AH
VRTX icon

Andreas Halvorsen’s Vertex Pharmaceuticals VRTX Stock Holding History

Andreas Halvorsen’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,421,673
Closed -$179M – 79
2015
Q4 		$179M Buy
1,421,673
+77,209
+6% +$9.32M 0.67% 35
2015
Q3 		$140M Sell
1,344,464
-460,722
-26% -$59.2M 0.54% 43
2015
Q2 		$223M Buy
1,805,186
+35,036
+2% +$4.41M 0.84% 32
2015
Q1 		$209M Buy
1,770,150
+1,005,950
+132% +$121M 0.81% 35
2014
Q4 		$90.8M Buy
+764,200
New +$86.1M 0.42% 48

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Andreas Halvorsen's VRTX Position: Q1 2016 in Review

Andreas Halvorsen sold out of Vertex Pharmaceuticals (VRTX) in Q1 2016, closing a stake of 1,421,673 shares — an estimated $179M sold.

Andreas Halvorsen first reported a position in VRTX in Q4 2014 and held it in 5 quarters. The position peaked at $223M in Q2 2015. 503 funds tracked by Wall St. Rank hold VRTX as of Q1 2016.

  • Andreas Halvorsen reported no remaining Vertex Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Andreas Halvorsen sold 1,421,673 Vertex Pharmaceuticals shares in Q1 2016, an estimated $179M.
  • Andreas Halvorsen first reported a position in Vertex Pharmaceuticals in Q4 2014 and held it in 5 quarters.
  • Andreas Halvorsen's Vertex Pharmaceuticals position peaked at $223M in Q2 2015.
  • 503 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2016.

Based on Viking Global Investors's 13F filing for Q1 2016, filed 16 May 2016.